




Blood sampling and laboratory methods 
Blood samples for determination of hs-cTnT and I were collected into tubes 
containing potassium EDTA or serum at presentation to the ED and serially 
thereafter. Serial sampling was discontinued when a patient was discharged or 
transferred to the catheter laboratory for treatment.  After centrifugation, samples 
were either analysed directly or frozen at -80°C until they were assayed in a blinded 
fashion in a dedicated core laboratory.  
According to the manufacturer, the hs-cTnT assay (Elecsys 2010 high-
sensitivity troponin T, Roche Diagnostics, Rotkreuz, Switzerland) has a 99th 
percentile concentration of 14 ng/L with a corresponding coefficient of variation (CV) 
of 10% at 13 ng/L.[22] Limit of blank (LoB) and limit of detection (LoD) have been 
determined to be 3 ng/L and 5 ng/L. None of the hs-cTnT measurements in this 
analysis were affected by the 2010-2012 calibration shift.[23]  
The hs-cTnI assay (ARCHITECT High Sensitive STAT Troponin I, Abbott 
Laboratories, IL, USA) has a 99th percentile concentration of 26.2 ng/L with a 
corresponding CV of <5% and a limit of detection (LoD) of 1.9 ng/L.[24] 
 
ESC hs-cTnT/I-0/1h-algorithms  
The ESC hs-cTnT/I-0/1h-algorithms were optimized for the early rule-out and rule-in 
of AMI and incorporate assay-specific hs-cTnT/I concentrations at ED presentation 
and their absolute changes within 1h.[4] Selection of these two parameters was 
based on the very high diagnostic accuracy for AMI achieved.[16][25] The algorithms 
for hs-cTnT (Elecsys) and hs-cTnI (Architect) were derived and validated in recent 
studies.[10][16][19][26]  
The rule-out criteria for hs-cTnT are defined as an undetectable (<5 ng/L) 
concentration at presentation or a baseline hs-cTnT concentration of less than 12 
ng/L and an absolute change within the first 1 hour of less than 3 ng/L. Rule-in is 
defined by a baseline hs-cTnT concentration of at least 52 ng/L or an absolute 
change in hs-cTnT within the first 1 hour of at least 5 ng/L.  
The rule-out criteria for hs-cTnI were defined as undetectable concentration 
(<2 ng/L) at presentation or a baseline hs-cTnI concentration of less than 5 ng/L and 
an absolute change within the first 1 hour of less than 2 ng/L. Rule-in is defined by a 
baseline hs-cTnI concentration of at least 52 ng/L or an absolute change in hs-cTnI 
within the first 1 hour of at least 6 ng/L. The remaining patients were triaged towards 




Algorithms using hs-cTnI 
A total of 2828 patients were eligible for the analysis using hs-cTnI (Supplemental 
Figure 1B). Patients triaged towards rule-out by the ESC hs-cTnI-0/1h-algorithm and its 
extended algorithm were younger, and less often had cardiovascular risk factors, 
preexisting CAD, ECG abnormalities, and cardiovascular medication, Supplemental 
Table 5 and 6).  
 
Prognostic performance for MACE 
MACE was adjudicated in 480 patients (17%, Supplemental Table 7 and 8). The 
ESC hs-cTnI-0/1h-algorithm triaged significantly more patients towards rule-out as 
compared to the extended algorithm 52% (95%CI 49.9-53.6) versus 27% (95%CI 
25.1-28.4), p<0.001).  
Among patients triaged towards rule-out, MACE rate was 0.9% (95%CI 0.5-1.5%) for 
the ESC hs-cTnI-0/1h-algorithm and 0.1% (95%CI 0.0-0.6%) for the extended 
algorithm. This resulted in a sensitivity of 97.3% (95%CI 95.4-98.4) versus 99.8% 
(95%CI 98.8-100), NPV of 99.1% (95%CI 98.5-99.5) versus 99.9% (95%CI 99.3-
100), p<0.01 and p=0.033, respectively; Supplemental Figure 3A,3B and 3C. 
Supplemental Table 9). 
Among patients triaged towards rule-in, specificity and PPV for MACE were 
comparable using the ESC hs-cTnI-0/1h-algorithm and the extended algorithm 
(Specificity: 90.7% (95%CI 89.5-91.8) versus 88.3% (95%CI 87-89.5) p=0.301) and 
PPV: 63.3% (95%CI 59.3-67.1) versus 60.4% (95%CI 56.9-63.8) p=0.671) 
(Supplemental Figure 3A,3B and 3C, Supplemental Table 9). 
Overall-efficacy (rule-out or rule-in) was also higher for the ESC hs-cTnI-0/1h-
algorithm versus the extended algorithm (73% (95%CI 71.1-74.4) versus 49% 
(95%CI 47.2-50.9), p<0.001; Supplemental Figure 3A and 3B). 
 
Prognostic performance for MACE+UA 
Among patients triaged towards rule-out, MACE+UA rate was 6.8% (95%CI 5.5-8.2) 
for the ESC hs-cTnI-0/1h-algorithm and 1.5% (95%CI 0.7-2.6) for the extended 
algorithm (Supplemental Figure 3A, 3B and 3C and Supplemental Table 7 and 8). 
Among patients triaged towards rule-out, the ESC hs-cTnI-0/1h-algorithm had higher 
sensitivity, NPV and negative LR as compared to the extended algorithm: 86.5% 
(95%CI 83.9-88.8) versus 98.5 (95%CI 97.3-99.2); p<0.001; 93.2 (95%CI 91.8-94.4) 
versus 98.5 (95%CI 97.4-99.2); p<0.001; and 0.21 (95%CI 0.17-0.25) versus 0.04 
(95%CI 0.02-0.08), respectively (Supplemental Table 9). 
Subgroup analyses using the hs-cTnI assay resulted in similar findings as compared 
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Supplemental Table 2 Baseline Characteristics ESC hs-cTn-0/1h-algorithm using hs-cTnT 
    
  
all patients Rule-Out Observe Zone Rule-In 
    (n = 3123) (n = 1880; 60%) (n = 738; 24%) (n = 505; 16%) 
Age, years, median (IQR) 61 (49 - 74) 54 (44 - 64) 74 (65 - 81) 72 (59 - 80) 
Male, sex, n (%) 2116 68% 1226 65% 544 74% 346 69% 
BMI, kg/m², median (IQR) 27 (24 - 30) 26 (24 - 30) 27 (24 - 30) 26 (24 - 29) 
Risk factors, n (%)                 
 
Hypertension 1911 61% 914 49% 629 85% 368 73% 
 
Hypercholesterolemia 1538 49% 746 40% 501 68% 291 58% 
 
Diabetes 550 18% 232 12% 199 27% 119 24% 
 
Current smoking 782 25% 558 30% 113 15% 111 22% 
 
History of smoking 1172 38% 621 33% 335 45% 216 43% 
History, n (%)                 
 
Coronary artery disease 1038 33% 442 24% 404 55% 192 38% 
 
Previous myocardial infarction 742 24% 302 16% 290 39% 150 30% 
 
Previous revascularization 858 28% 380 20% 332 45% 146 29% 
 
Peripheral artery disease 162 5.2% 43 2.3% 70 9.5% 49 9.7% 
 
Previous stroke 174 5.6% 61 3.2% 64 8.7% 49 9.7% 
  Positive family history 469 15% 318 17% 78 11.0% 73 15% 
Chest pain onset ≤3h 1179 38% 745 40% 241 33% 193 38% 
Chest pain onset >3h 1944 62% 1135 60% 497 67% 312 62% 
ECG findings, n (%)                 
 
Left bundle branch block 117 3.7% 24 1.3% 56 7.6% 37 7.3% 
 
ST-segment elevation 53 1.7% 38 2.0% 9 1.2% 6 1.2% 
 
ST-segment depression 323 10% 72 3.8% 105 14% 146 29% 
 
T-wave inversion 343 11% 103 5.5% 129 18% 111 22% 
 
No significant ECG abnormalities 2276 74% 1545 82% 473 64% 258 51% 
Medication at entry n (%)                 
 
Aspirin/Thienopyridin 1211 39% 543 29% 440 60% 228 45% 
 
B-blockers 1078 35% 484 26% 403 55% 191 38% 
 
ACE/AT2- Inhibitors 1230 39% 536 29% 458 62% 236 47% 
 
Calcium- Antagonists 467 15% 195 10% 180 24% 92 18% 
 
Nitrates 337 11% 109 5.8% 152 21% 76 15% 
 
Statins 1110 36% 508 27% 410 56% 192 38% 
in hospital procedures n (%)                 
 
Coronary angiography 715 23% 177 9.4% 207 28% 331 66% 
 
Percutaneous coronary intervention  402 13% 73 3.9% 118 16% 211 42% 
 
CABG 60 1.9% 7 0.4% 19 2.6% 34 6.7% 
 
Ergometry 744 24% 470 25% 192 26% 82 16% 
  Myocardial perfusion scanning 324 10% 169 9.0% 122 17% 33 6.5% 
Table Legend: BMI: body mass index; BNP: brain natiruretic peptide; ECG: electrocardiography. 
   ACE: angiotensin converting enzyme; AT1: angiotensin 1; CABG: coronary artery bypass graft; IQR:  interquatile ranges. 










Supplemental Table 3 Baseline Characteristics Extended Algorithm using hs-cTnT 
    
  
all patients Rule-Out Observe Zone Rule-In 
    (n = 3123) (n = 1393; 45%) (n = 928; 30%) (n = 802; 26%) 
Age, years, median (IQR) 61 (49 - 74) 53 (43 - 63) 66 (54 - 76) 74 (61 - 81) 
Male, sex, n (%) 2116 68% 898 65% 653 70% 565 70% 
BMI, kg/m², median (IQR) 27 (24 - 30) 26 (24 - 30)  27 (24 - 30) 26 (24 - 29) 
Risk factors, n (%)                 
 
Hypertension 1911 61% 609 44% 673 73% 629 78% 
 
Hypercholesterolemia 1538 49% 469 34% 559 60% 510 64% 
 
Diabetes 550 18% 145 10.0% 198 21% 207 26% 
 
Current smoking 782 25% 431 31% 198 21% 153 19% 
 
History of smoking 1172 38% 440 32% 372 40% 360 45% 
History, n (%)                 
 
Coronary artery disease 1038 33% 238 17% 422 46% 378 47% 
 
Previous myocardial infarction 742 24% 159 11% 302 33% 281 35% 
 
Previous revascularization 858 28% 205 15% 351 38% 302 38% 
 
Peripheral artery disease 162 5.2% 27 1.9% 51 5.5% 84 11% 
 
Previous stroke 174 5.6% 45 3.2% 54 5.8% 75 9.4% 
  Positive family history 469 15% 231 17% 131 14% 107 13% 
Chest pain onset <3h 1179 38% 565 41% 328 35% 286 36% 
Chest pain onset <3h 1944 62% 828 59% 600 65% 516 64% 
ECG findings, n (%)                 
 
Left bundle branch block 117 3.7% 14 1.0% 51 5.5% 52 6.5% 
 
ST-segment elevation 53 1.7% 0 0% 40 4.3% 13 1.6% 
 
ST-segment depression 323 10% 0 0% 93 10% 230 29% 
 
T-wave inversion 343 11% 0 0% 134 14% 209 26% 
 
No significant ECG abnormalities 2276 74% 1393 100% 526 57% 357 45% 
Medication at entry n (%)                 
 
Aspirin/Thienopyridin 1211 39% 311 22% 467 50% 433 54% 
 
B-blockers 1078 35% 296 21% 413 45% 369 46% 
 
ACE/AT2- Inhibitors 1230 39% 331 24% 477 51% 422 53% 
 
Calcium- Antagonists 467 15% 126 9% 159 17% 182 23% 
 
Nitrates 337 11% 59 4.2% 120 13% 158 20% 
 
Statins 1110 36% 293 21% 442 48% 375 47% 
in hospital procedures n (%)                 
 
Coronary angiography 715 23% 70 5.0% 190 21% 455 57% 
 
Percutaneous coronary intervention  402 13% 23 1.7% 97 11.0% 282 35% 
 
CABG 60 1.9% 3 0.2% 13 1.4% 44 5.5% 
 
Ergometry 744 24% 303 22% 287 31% 154 19% 
  Myocardial perfusion scanning 324 10% 97 7.0% 145 16% 82 10% 
Table Legend: BMI: body mass index; BNP: brain natiruretic peptide; ECG: electrocardiography. 
   ACE: angiotensin converting enzyme; AT1: angiotensin 1; CABG: coronary artery bypass graft; IQR:  interquatile ranges. 



































82# male 12 20 yes 11 11 no no AV Block arrhythmic disorder 
                      
47 female 2 40 no 8 11 yes no - NSTEMI  
                      
62 male 1 60 yes 10 10 no no cardiac death aortic dissection 
                      
53 male 12 90 yes 7 10 no yes NSTEMI 28 days later UA 
                      
73 female 4 50 no 10 10 no yes AV Block pneumonia 
                      
74 female 1 40 no 10 12 yes no - NSTEMI 
                      
73 female 4 30 no 10 10 no no AV Block arrhythmic disorder 
                      
63 female 3 70 no 8 10 no no NSTEMI 8 days later 
arrhythmic 
disorder 
                      
67 female 1 30 no 6 7 no no - NSTEMI 
                      
86 female 4 80 yes 8 7 no no - NSTEMI 
                      
62 female 6 90 no 5 5 no yes NSTEMI 2 days later UA 
                      
72# female 8 0 no 9 9 no no cardiac arrest neoplasia 
                      
Table legend: * for MACE; # also missed patients by extended algorithm; 
     CPO: chest pain onset; ACS: acute coronary syndrome; CAD: coronary artery disease; hs-cTnT: high sensitivity cardiac troponin T;  
 MACE: major adverse cardiac events; AV-Block: atrioventricular block; 
      NSTEMI: non ST-segment elevation myocardial infarction (all Type 1 Myocardial Infarction); UA: unstable angina  















Supplemental Table 5 Baseline Characteristics ESC hs-cTn 0/1h-algorithm  using hs-cTnI 
    
  
All patients Rule-Out Observe Zone Rule-In 
    (n = 2828) (n = 1464; 52%) (n = 770; 27%) (n = 594; 21%) 
Age, years, median (IQR) 62 49-74 53 43-64 72 60-80 70 57-79 
Male, sex, n (%) 1928 68% 959 66% 553 72% 416 70% 
BMI, kg/m², median (IQR) 27 24-30 26 24-29 27 25-30% 27 24-29 
Risk factors, n (%)                 
 
Hypertension 1731 61% 675 46% 625 81% 431 73% 
 
Hypercholesterolemia 1390 49% 550 37% 498 65% 342 58% 
 
Diabetes 507 18% 180 12% 184 24% 143 24% 
 
Current smoking 709 25% 441 30% 127 17% 141 24% 
 
History of smoking 1070 38% 473 32% 345 45% 252 42% 
History, n (%)                 
 
Coronary artery disease 941 33% 309 21% 392 51% 240 40% 
 
Previous myocardial infarction 665 24% 197 14% 289 38% 179 30% 
 
Previous revascularization 770 27% 266 18% 317 41% 187 32% 
 
Peripheral artery disease 147 5.2% 26 1.8% 64 8.3% 57 9.6% 
 
Previous stroke 161 5.7% 50 3.4% 60 7.8% 51 8.6% 
  Positive family history 420 15% 239 16% 89 12.0% 92 16% 
Chest pain onset ≤3h 1050 37% 586 40% 257 33% 207 35% 
Chest pain onset >3h 1778 63% 878 60% 513 67% 387 65% 
ECG findings, n (%)                 
 
Left bundle branch block 109 3.9% 17 1.2% 58 7.5% 34 5.7% 
 
ST-segment elevation 48 1.7% 26 1.8% 8 1.0% 14 2.4% 
 
ST-segment depression 291 10% 48 3.3% 94 12% 149 25% 
 
T-wave inversion 312 11% 72 4.9% 118 15% 122 21% 
 
No significant ECG abnormalities 2111 75% 1265 86% 516 67% 330 56% 
Medication at entry n (%)                 
 
Aspirin/Thienopyridin 1091 39% 383 26% 425 55% 283 48% 
 
B-blockers 955 34% 333 23% 385 50% 237 40% 
 
ACE/AT2-Inhibitors 1099 39% 373 26% 440 57% 286 48% 
 
Calcium-Antagonists 422 15% 135 9.2% 178 23% 109 18% 
 
Nitrates 306 11% 76 5.2% 138 18% 92 16% 
 
Statins 989 35% 367 25% 394 51% 228 38% 
in hospital procedures n (%)                 
 
Coronary angiography 656 23% 126 8.6% 180 23% 350 59% 
 
Percutaneous coronary intervention  371 13% 47 3.2% 95 12% 229 39% 
 
CABG 55 1.9% 3 0.2% 19 2.5% 33 5.6% 
 
Ergometry 679 24% 353 24% 206 27% 120 20% 
  Myocardial perfusion scanning 304 11% 123 8.4% 127 17% 54 9.1% 
Table Legend: BMI: body mass index; BNP: brain natiruretic peptide; ECG: electrocardiography. 
   ACE: angiotensin converting enzyme; AT1: angiotensin 1; CABG: coronary artery bypass graft; IQR:  interquatile ranges. 










Supplemental Table 6 Baseline Characteristics Extended Algorithm using hs-cTnI 
    
  
all patients Rule-Out Observe Zone Rule-In 
    (n = 2828) (n = 755; 27%) (n = 1442; 51%) (n = 631; 22%) 
Age, years, median (IQR) 62 49-74 49 39-60 65 53-76 70 57-79 
Male, sex, n (%) 1928 68% 477 25% 1010 70% 441 70% 
BMI, kg/m², median (IQR) 27 24-30 26 23-29 27 24-30 27 24-29 
Risk factors, n (%)                 
 
Hypertension 1731 61% 267 35% 1000 69% 464 74% 
 
Hypercholesterolemia 1390 49% 199 26% 829 58% 362 57% 
 
Diabetes 507 18% 63 8.3% 291 20% 153 24% 
 
Current smoking 709 25% 238 32% 324 23% 147 23% 
 
History of smoking 1070 38% 234 31% 566 39% 270 43% 
History, n (%)                 
 
Coronary artery disease 941 33% 83 11% 593 41% 265 42% 
 
Previous myocardial infarction 665 24% 51 6.8% 417 29% 197 31% 
 
Previous revascularization 770 27% 74 10% 490 34% 206 33% 
 
Peripheral artery disease 147 5.2% 9 1.2% 74 5.1% 64 10% 
 
Previous stroke 161 5.7% 20 2.6% 87 6.0% 54 8.6% 
  Positive family history 420 15% 133 18% 187 13% 100 16% 
Chest pain onset ≤3h 1050 37% 298 40% 536 37% 216 34% 
Chest pain onset >3h 1778 63% 457 60% 906 63% 415 66% 
ECG findings, n (%)                 
 
Left bundle branch block 109 3.9% 6 1.0% 67 4.6% 36 5.7% 
 
ST-segment elevation 48 1.7% 0 0% 32 2.2% 16 2.5% 
 
ST-segment depression 291 10% 0 0% 128 8.9% 163 26% 
 
T-wave inversion 312 11% 0 0% 173 12.0% 139 22% 
 
No significant ECG abnormalities 2111 75% 755 99% 1019 71% 337 53% 
Medication at entry n (%)                 
 
Aspirin/Thienopyridin 1091 39% 105 14% 683 47% 303 48% 
 
B-blockers 955 34% 116 15% 582 40% 257 41% 
 
ACE/AT2-Inhibitors 1099 39% 129 17% 661 46% 309 49% 
 
Calcium-Antagonists 422 15% 48 6.4% 254 18% 120 19% 
 
Nitrates 306 11% 15 2.0% 187 13% 104 17% 
 
Statins 989 35% 111 15% 632 44% 246 39% 
in hospital procedures n (%)                 
 
Coronary angiography 656 23% 22 2.9% 265 18% 369 59% 
 
Percutaneous coronary intervention  371 13% 6 1.0% 122 8.5% 243 39% 
 
CABG 55 1.9% 0 0% 19 1.3% 36 5.7% 
 
Ergometry 679 24% 107 14% 449 31% 123 20% 
  Myocardial perfusion scanning 304 11% 26 3.4% 222 15% 56 8.9% 
Table Legend: BMI: body mass index; BNP: brain natiruretic peptide; ECG: electrocardiography. 
   ACE: angiotensin converting enzyme; AT1: angiotensin 1; CABG: coronary artery bypass graft; IQR:  interquatile ranges. 










Supplemental Table 7 MACE ESC hs-cTnI 0/1h-algorithm using hs-cTnI 
    
  
all patients Rule-Out Observe Zone Rule-In 
    (n = 2828) (n = 1464; 52%) (n = 770; 27%) (n = 594; 21%) 
MACE  480 17% 13 0.9% 91 12% 376 63% 
MACE+UA 734 26% 99 6.8% 225 29% 410 69% 
 
T1MI during index visit 393 14% 3 0.2% 57 7.4% 333 56% 
 
T2MI during index visit 57 2.0% 4 0.3% 14 1.8% 39 6.6% 
 
T1MI during follow up 33 1.2% 3 0.2% 13 1.7% 17 2.9% 
 
UA 272 9.6% 89 6.1% 145 19% 38 6.4% 
 
Cardiogenic shock 8 0.3% 0 0% 1 0.1% 7 1.2% 
 
Ventricular arrhythmia 5 0.2% 0 0% 2 0.3% 3 0.5% 
 
High-grade AV Block 9 0.3% 2 0.1% 2 0.3% 5 0.8% 
 
Cardiac death 16 0.6% 0 0% 4 0.5% 12 2.0% 
  Non cardiac death 9 0.3% 1 0.1% 5 0.6% 3 0.5% 
Table Legend: MACE: major adverse cardiac event, MACE-UA: major adverse cardiac event with unstable angina 










Supplemental Table 8 MACE Extended Algorithm using hs-cTnI 
     
  
all patients Rule-Out Observe Zone Rule-In 
     (n = 2828) (n = 755; 27%) (n = 1442; 51%) (n = 631; 23%) 
 MACE  480 17% 1 0.1% 87 6.0% 392 62% 
 MACE+UA 734 26% 11 1.5% 290 20% 433 69% 
 
 
T1MI during index visit 393 14% 0 0% 52 4.9% 366 56% 
 
 
T2MI during index visit 57 2.0% 0 0.0% 13 1.2% 42 6.6% 
 
 
T1MI during follow up 33 1.2% 0 0% 14 1.0% 19 3.0% 
 
 
UA 272 9.6% 10 1.3% 189 18% 46 7.0% 
 
 
Cardiogenic shock 8 0.3% 0 0% 0 0% 8 1.3% 
 
 
Ventricular arrhythmia 5 0.2% 0 0% 2 0.1% 3 0.5% 
 
 
High-grade AV Block 9 0.3% 0 0% 4 0.3% 5 0.8% 
 
 
Cardiac death 16 0.6% 0 0% 3 0.2% 13 2.1% 
   Non cardiac death 9 0.3% 1 0.1% 3 0.2% 5 0.8% 
 Table Legend: MACE: major adverse cardiac event, MACE-UA: major adverse cardiac event with unstable angina 










Supplemental Table 9 
     hs-cTnI Algorithmic diagnostic perfomance for MACE    
  
 
ESC hs-cTnI-0/1h-algorithm  Extended Algorithm 
   
 
% (95% CI) % (95% CI) 
   Rule-Out n = 1464 n = 755 p-value 
      Sensitivity 97.3 (95.4-98.4) 99.4 (98.2-99.8) p<0.001 
      NPV 99.1 (98.5-99.5) 99.7 (99.2-99.9) p=0.004 
      Neg. LR 0.04 (0.03-0.08) 0.01(0.00-0.04) 
   
      Rule-In n = 594 n =631   
      Specificity 90.7 (89.5-91.8) 89.7 (88.4-90.9) p<0.001 
      PPV 63.3 (59.3-67.1) 61.9 (58.1-65.6) p=0.011 
      Pos. LR 8.44 (7.37-9.66) 7.94 (7-9.02)   
  
       hs-cTnI Algorithmic diagnostic perfomance for MACE+UA   
  
 
ESC hs-cTnI-0/1h-algorithm  Extended Algorithm 
   
 
% (95% CI) % (95% CI) 
   
      Rule-Out n = 1464 n = 755 p-value 
      Sensitivity 86.5 (83.9-88.8) 94.7(92.7-96) p<0.001 
      NPV 93.2 (91.8-94.4) 96.5 (95.3-97.4) p<0.001 
      Neg. LR 0.21 (0.17-0.25) 0.10 (0.08-0.14) 
   
      Rule-In n = 594 n = 631   
      Specificity 91.2 (98.9-92.4) 90.4 (89.1-91.6) p<0.001 
      PPV 69.0 (65.2-72.6) 68.3 (64.6-71.8) p=0.194 
      Pos. LR 6.36 (5.46-7.40) 6.16 (5.33-7.12)   
  Table Legend: MACE: major adverse cardiac event, MACE+UA: major adverse cardiac event with unstable angina 
CI: confidence interval.NPV: negative predictive value, PPV: positive predictive value,  
  
neg. LR: negative likelihood ratio, pos. LR: positive likelihood ratio 



















Supplemental Table 10 
    hs-cTnT Algorithmic diagnostic perfomance for MACE without T2MI 
  
 
ESC hs-cTnT-0/1h-algorithm  Extended Algorithm 
  
 
% (95% CI) % (95% CI) 
  Rule-Out n = 1880 n = 1393 
      Sensitivity 97.4 (95.6 - 98.5) 98.9 (97.5 - 99.5) 
      NPV 99.4 (98.6 - 99.9) 99.6 (99.2 - 99.8) 




   Rule-In n = 505 n = 802 
      Specificity 94.2 (93.2 - 95) 85.9 (84.5 - 90.9) 
      PPV 69.5 (65.4 - 73.4) 53.2 (49.8 - 56.7) 
      Pos. LR 12.87 (10.94 - 15.13) 6.43 (5.83 - 7.09) 
  
      hs-cTnI Algorithmic diagnostic perfomance for MACE without T2MI 
  
 
ESC hs-cTnI-0/1h-algorithm  Extended Algorithm 
  
 
% (95% CI) % (95% CI) 
  
     Rule-Out n = 1464 n = 755 
      Sensitivity 97.9 (96.1 - 98.9) 99.8 (98.7 - 100) 
      NPV 99.4 (98.8 - 99.7) 99.9 (99.5 - 100) 
      Neg. LR 0.03 (0.02 - 0.07) 0.00 (0.00 - 0.03) 
  
     Rule-In n = 594 n = 631 
      Specificity 89.6 (88.4 - 90.8) 88.6 (87.3 - 89.8) 
      PPV 58.2 (54.2 - 62.1) 57 (53.1 - 60.8) 
      Pos. LR 7.68 (6.76 - 8.72) 7.29 (6.48 - 8.22) 
  Table Legend: MACE: major adverse cardiac event, MACE+UA: major adverse cardiac event with unstable angina 
CI: confidence interval.NPV: negative predictive value, PPV: positive predictive value,  
 
neg. LR: negative likelihood ratio, pos. LR: positive likelihood ratio 



















Supplemental Table 11 hs-cTnT algorithmic performance in Subgroup Analysis 
  Rule-out ESC hs-cTnT 0/1h-Algorithm for MACE   
   Sensitivity  (95%CI) Specificity  (95%CI) NPV  (95%CI) PPV  (95%CI) 
 females 0.939 (0.888  to  0.967) 0.752 (0.722  to  0.78) 0.986 (0.974  to  0.993) 0.393 (0.343  to  0.445) 
 males 0.992 (0.977  to  0.997) 0.703 (0.681  to  0.724) 0.998 (0.993  to  0.999) 0.420 (0.388  to  0.453) 
 ≥ 62 
years 0.974 (0.953  to  0.986) 0.511 (0.482  to  0.54) 0.984 (0.97  to  0.991) 0.398 (0.367  to  0.429) 
 < 62 
years 0.985 (0.948  to  0.996) 0.890 (0.873  to  0.905) 0.998 (0.994  to  1) 0.460 (0.404  to  0.518) 
 CAD 0.984 (0.96  to  0.994) 0.557 (0.522  to  0.591) 0.991 (0.977  to  0.996) 0.414 (0.376  to  0.454) 
 non-CAD 0.971 (0.943  to  0.985) 0.790 (0.771  to  0.808) 0.994 (0.989  to  0.997) 0.411 (0.374  to  0.449) 
 cpo ≤ 2h 0.971 (0.928  to  0.989) 0.770 (0.737  to  0.8) 0.993 (0.981  to  0.997) 0.457 (0.401  to  0.515) 
 cpo > 2h 0.982 (0.963  to  0.991) 0.701 (0.68  to  0.722) 0.995 (0.989  to  0.997) 0.399 (0.369  to  0.431) 
 eGFR ≤ 
60 0.986 (0.952  to  0.996) 0.273 (0.227  to  0.324) 0.978 (0.923  to  0.994) 0.380 (0.332  to  0.429) 
 eGFR > 
60 0.973 (0.952  to  0.985) 0.784 (0.766  to  0.8) 0.994 (0.99  to  0.997) 0.427 (0.395  to  0.461) 
 Rule-out ESC hs-cTnT 0/1h-Algorithm for MACE+UA 
   Sensitivity  (95%CI) Specificity  (95%CI) NPV  (95%CI) PPV  (95%CI) 
 females 0.810 (0.749  to  0.859) 0.762 (0.732  to  0.79) 0.944 (0.923  to  0.959) 0.450 (0.399  to  0.502) 
 males 0.805 (0.772  to  0.835) 0.736 (0.713  to  0.757) 0.903 (0.885  to  0.918) 0.553 (0.52  to  0.585) 
 ≥ 62 
years 0.838 (0.806  to  0.865) 0.529 (0.498  to  0.561) 0.842 (0.811  to  0.869) 0.521 (0.489  to  0.553) 
 < 62 
years 0.721 (0.657  to  0.777) 0.899 (0.882  to  0.914) 0.953 (0.94  to  0.963) 0.533 (0.475  to  0.589) 
 CAD 0.760 (0.719  to  0.796) 0.577 (0.536  to  0.617) 0.747 (0.704  to  0.785) 0.594 (0.554  to  0.633) 
 non-CAD 0.871 (0.831  to  0.902) 0.800 (0.781  to  0.818) 0.969 (0.959  to  0.977) 0.459 (0.421  to  0.498) 
 cpo ≤ 2h 0.826 (0.766  to  0.872) 0.792 (0.759  to  0.822) 0.937 (0.913  to  0.954) 0.549 (0.492  to  0.605) 
 cpo > 2h 0.801 (0.767  to  0.831) 0.728 (0.706  to  0.749) 0.909 (0.893  to  0.923) 0.518 (0.486  to  0.549) 
 eGFR ≤ 
60 0.928 (0.884  to  0.956) 0.287 (0.236  to  0.344) 0.835 (0.746  to  0.897) 0.505 (0.455  to  0.555) 
 
eGFR > 
60 0.763 (0.727  to  0.795) 0.804 (0.786  to  0.82) 0.921 (0.907  to  0.933) 0.530 (0.497  to  0.564) 
 Rule-out Extended Algorithm for MACE 
   Sensitivity  (95%CI) Specificity  (95%CI) NPV  (95%CI) PPV  (95%CI) 
 females 0.993 (0.962  to  0.999) 0.395 (0.363  to  0.428) 0.997 (0.984  to  0.999) 0.219 (0.189  to  0.252) 
 males 0.997 (0.985  to  1) 0.330 (0.308  to  0.353) 0.998 (0.99  to  1) 0.244 (0.223  to  0.266) 
 ≥ 62 
years 0.995 (0.981  to  0.999) 0.178 (0.157  to  0.201) 0.990 (0.966  to  0.997) 0.286 (0.263  to  0.311) 
 < 62 
years 1.000 (0.973  to  1) 0.494 (0.468  to  0.52) 1.000 (0.995  to  1) 0.158 (0.135  to  0.184) 
 CAD 0.996 (0.978  to  0.999) 0.144 (0.121  to  0.17) 0.991 (0.952  to  0.998) 0.271 (0.243  to  0.3) 
 non-CAD 0.996 (0.98  to  0.999) 0.442 (0.419  to  0.465) 0.999 (0.993  to  1) 0.212 (0.191  to  0.235) 
 cpo ≤ 2h 1.000 (0.973  to  1) 0.380 (0.345  to  0.417) 1.000 (0.986  to  1) 0.243 (0.21  to  0.28) 
 cpo > 2h 0.995 (0.981  to  0.999) 0.342 (0.321  to  0.364) 0.997 (0.989  to  0.999) 0.234 (0.214  to  0.255) 
 eGFR ≤ 
60 0.986 (0.952  to  0.996) 0.089 (0.063  to  0.125) 0.935 (0.793  to  0.982) 0.328 (0.286  to  0.373) 
 eGFR > 
60 1.000 (0.99  to  1) 0.390 (0.37  to  0.41) 1.000 (0.996  to  1) 0.214 (0.195  to  0.233) 
 Rule-out Extended Algorithm for MACE+UA 
   Sensitivity  (95%CI) Specificity  (95%CI) NPV  (95%CI) PPV  (95%CI) 
 females 0.969 (0.935  to  0.986) 0.413 (0.379  to  0.447) 0.982 (0.962  to  0.992) 0.284 (0.251  to  0.319) 
 males 0.977 (0.962  to  0.986) 0.373 (0.349  to  0.397) 0.976 (0.96  to  0.985) 0.387 (0.363  to  0.412) 
 ≥ 62 
years 0.976 (0.961  to  0.986) 0.203 (0.179  to  0.229) 0.933 (0.891  to  0.96) 0.428 (0.402  to  0.455) 
 < 62 
years 0.972 (0.94  to  0.987) 0.519 (0.492  to  0.545) 0.992 (0.982  to  0.996) 0.243 (0.216  to  0.273) 
 CAD 0.970 (0.95  to  0.982) 0.175 (0.146  to  0.208) 0.877 (0.804  to  0.925) 0.489 (0.457  to  0.521) 
 non-CAD 0.982 (0.962  to  0.992) 0.456 (0.433  to  0.48) 0.993 (0.984  to  0.997) 0.260 (0.237  to  0.285) 
 cpo ≤ 2h 0.979 (0.948  to  0.992) 0.408 (0.37  to  0.447) 0.985 (0.962  to  0.994) 0.337 (0.299  to  0.377) 
 cpo > 2h 0.974 (0.958  to  0.984) 0.380 (0.357  to  0.403) 0.975 (0.96  to  0.985) 0.364 (0.341  to  0.388) 




60 0.973 (0.957  to  0.983) 0.424 (0.403  to  0.445) 0.982 (0.971  to  0.989) 0.329 (0.308  to  0.352) 
 Table Legend: MACE: major adverse cardiac event,MACE+UA: major adverse cardiac event with unstable angina 
 CI: confidence interval, CAD: coronary artery disease, cpo: chest pain onset, eGFR: estimated glomerular filtration rate, 
NPV: negative predictive value, PPV: positive predictive value 
















Supplemental Table 12  hs-cTnI algorithmic performance in Subgroup Analysis  
  Rule-out ESC hs-cTnI 0/1h-Algorithm for MACE   
   Sensitivity  (95%CI) Specificity  (95%CI) NPV  (95%CI) PPV  (95%CI) 
 females 0.956 (0.906  to  0.979) 0.652 (0.618  to  0.685) 0.988 (0.974  to  0.995) 0.327 (0.282  to  0.374) 
 males 0.980 (0.959  to  0.99) 0.603 (0.578  to  0.626) 0.993 (0.985  to  0.996) 0.350 (0.32  to  0.38) 
 ≥ 62 
years 0.966 (0.942  to  0.981) 0.421 (0.392  to  0.451) 0.974 (0.955  to  0.985) 0.359 (0.33  to  0.39) 
 < 62 
years 0.992 (0.955  to  0.999) 0.782 (0.759  to  0.804) 0.999 (0.994  to  1) 0.303 (0.261  to  0.35) 
 CAD 0.970 (0.939  to  0.985) 0.427 (0.391  to  0.463) 0.977 (0.954  to  0.989) 0.358 (0.321  to  0.396) 
 non-CAD 0.976 (0.948  to  0.989) 0.702 (0.679  to  0.723) 0.995 (0.989  to  0.998) 0.330 (0.297  to  0.365) 
 cpo ≤ 2h 0.984 (0.944  to  0.996) 0.683 (0.646  to  0.719) 0.995 (0.983  to  0.999) 0.386 (0.334  to  0.44) 
 cpo > 2h 0.969 (0.945  to  0.982) 0.596 (0.572  to  0.619) 0.989 (0.981  to  0.994) 0.329 (0.301  to  0.359) 
 eGFR ≤ 
60 0.978 (0.938  to  0.993) 0.266 (0.219  to  0.32) 0.963 (0.895  to  0.987) 0.389 (0.339  to  0.441) 
 eGFR > 
60 0.971 (0.947  to  0.984) 0.668 (0.648  to  0.688) 0.993 (0.987  to  0.996) 0.327 (0.299  to  0.356) 
 Rule-out ESC hs-cTnI 0/1h-Algorithm for MACE+UA 
   Sensitivity  (95%CI) Specificity  (95%CI) NPV  (95%CI) PPV  (95%CI) 
 females 0.866 (0.808  to  0.908) 0.667 (0.632  to  0.701) 0.952 (0.93  to  0.968) 0.392 (0.346  to  0.441) 
 males 0.865 (0.834  to  0.891) 0.645 (0.62  to  0.67) 0.922 (0.903  to  0.937) 0.496 (0.465  to  0.528) 
 ≥ 62 
years 0.879 (0.849  to  0.903) 0.450 (0.417  to  0.483) 0.857 (0.822  to  0.886) 0.498 (0.466  to  0.529) 
 < 62 
years 0.826 (0.766  to  0.874) 0.799 (0.775  to  0.82) 0.967 (0.954  to  0.977) 0.391 (0.344  to  0.439) 
 CAD 0.827 (0.788  to  0.86) 0.458 (0.415  to  0.501) 0.761 (0.71  to  0.805) 0.560 (0.521  to  0.598) 
 non-CAD 0.918 (0.882  to  0.944) 0.716 (0.693  to  0.738) 0.978 (0.968  to  0.985) 0.385 (0.35  to  0.421) 
 cpo ≤ 2h 0.893 (0.838  to  0.93) 0.716 (0.678  to  0.752) 0.955 (0.931  to  0.971) 0.495 (0.441  to  0.55) 
 cpo > 2h 0.855 (0.824  to  0.882) 0.630 (0.605  to  0.654) 0.922 (0.904  to  0.937) 0.458 (0.428  to  0.489) 
 eGFR ≤ 
60 0.932 (0.886  to  0.96) 0.283 (0.229  to  0.343) 0.838 (0.742  to  0.903) 0.510 (0.458  to  0.562) 
 
eGFR > 
60 0.841 (0.808  to  0.869) 0.700 (0.679  to  0.72) 0.938 (0.924  to  0.949) 0.450 (0.42  to  0.481) 
 Rule-out Extended Algorithm for MACE 
   Sensitivity  (95%CI) Specificity  (95%CI) NPV  (95%CI) PPV  (95%CI) 
 females 0.993 (0.959  to  0.999) 0.362 (0.329  to  0.397) 0.996 (0.98  to  0.999) 0.215 (0.185  to  0.249) 
 males 1.000 (0.989  to  1) 0.302 (0.28  to  0.325) 1.000 (0.992  to  1) 0.238 (0.217  to  0.261) 
 ≥ 62 
years 0.997 (0.984  to  1) 0.149 (0.129  to  0.171) 0.994 (0.965  to  0.999) 0.282 (0.258  to  0.308) 
 < 62 
years 1.000 (0.97  to  1) 0.465 (0.437  to  0.492) 1.000 (0.994  to  1) 0.152 (0.129  to  0.178) 
 CAD 1.000 (0.984  to  1) 0.117 (0.096  to  0.143) 1.000 (0.956  to  1) 0.272 (0.243  to  0.302) 
 non-CAD 0.996 (0.977  to  0.999) 0.410 (0.386  to  0.434) 0.999 (0.992  to  1) 0.203 (0.181  to  0.226) 
 cpo ≤ 2h 1.000 (0.97  to  1) 0.354 (0.317  to  0.392) 1.000 (0.983  to  1) 0.238 (0.204  to  0.276) 
 cpo > 2h 0.997 (0.984  to  0.999) 0.311 (0.289  to  0.333) 0.998 (0.989  to  1) 0.229 (0.209  to  0.251) 
 eGFR ≤ 
60 0.993 (0.96  to  0.999) 0.080 (0.054  to  0.117) 0.958 (0.798  to  0.993) 0.340 (0.295  to  0.388) 
 eGFR > 
60 1.000 (0.989  to  1) 0.356 (0.336  to  0.377) 1.000 (0.995  to  1) 0.205 (0.186  to  0.225) 
 Rule-out Extended Algorithm for MACE+UA 
   Sensitivity  (95%CI) Specificity  (95%CI) NPV  (95%CI) PPV  (95%CI) 
 females 0.983 (0.952  to  0.994) 0.381 (0.347  to  0.417) 0.989 (0.969  to  0.996) 0.283 (0.249  to  0.32) 
 males 0.986 (0.972  to  0.993) 0.342 (0.318  to  0.368) 0.983 (0.967  to  0.991) 0.377 (0.353  to  0.402) 
 ≥ 62 
years 0.985 (0.971  to  0.993) 0.172 (0.149  to  0.199) 0.950 (0.904  to  0.974) 0.425 (0.398  to  0.453) 
 < 62 
years 0.984 (0.955  to  0.995) 0.488 (0.46  to  0.516) 0.995 (0.985  to  0.998) 0.231 (0.203  to  0.261) 
 CAD 0.984 (0.967  to  0.992) 0.148 (0.12  to  0.182) 0.916 (0.836  to  0.959) 0.491 (0.457  to  0.524) 
 non-CAD 0.987 (0.967  to  0.995) 0.423 (0.399  to  0.448) 0.994 (0.985  to  0.998) 0.249 (0.225  to  0.274) 
 cpo ≤ 2h 0.983 (0.951  to  0.994) 0.381 (0.342  to  0.422) 0.986 (0.961  to  0.995) 0.331 (0.293  to  0.373) 
 cpo > 2h 0.986 (0.972  to  0.993) 0.348 (0.324  to  0.372) 0.985 (0.971  to  0.992) 0.356 (0.333  to  0.381) 




60 0.983 (0.969  to  0.991) 0.390 (0.368  to  0.412) 0.988 (0.977  to  0.994) 0.320 (0.298  to  0.343) 
 Table Legend: MACE: major adverse cardiac event,MACE+UA: major adverse cardiac event with unstable angina 
 CI: confidence interval, CAD: coronary artery disease, cpo: chest pain onset, eGFR: estimated glomerular filtration rate, 
NPV: negative predictive value, PPV: positive predictive value 

























Figure 1B Patient flow chart for hs-cTnI 
 
 
Troponin algorithm classifying patients into rule-out, observe and rule-in. hs-cTn 
values are presented in ng/L. 0h/1h = hs-cTnT at presentation and after 1 hour. Δ0h-
1h = absolute change of hs-cTnT within the first hour. MACE: major adverse cardiac 









Troponin algorithm classifying patients into rule-out, observe and rule-in. hs-cTn 
values are presented in ng/L. 0h/1h = hs-cTnI at presentation and after 1 hour. Δ0h-
1h = absolute change of hs-cTnI within the first hour. MACE: major adverse cardiac 











ESC hs-cTnI-0/1h-algorithm classifying patients into rule-out, observe and rule-in. hs-
cTn values are presented in ng/L. 0h/1h = hs-cTnI at presentation and after 1 hour. 
Δ0h-1h = absolute change of hs-cTnI within the first hour. MACE: major adverse 
cardiac event; MACE+UA: major adverse cardiac event with unstable angina; NPV: 
negative predictive value; PPV: positive predictive value, Pos.LR: positive likelihood 





Figure 3A ESC hs-cTnI 0/1h-algorithm: criteria and performance for hs-cTnI 
 
 
Troponin algorithm combined with ECG criteria and likelihood for acute coronary 
syndrome (ACS) classifying patients into rule-out, observe and rule-in. MACE: major 
adverse cardiac event; MACE+UA: major adverse cardiac event with unstable 
angina; NPV: negative predictive value; PPV: positive predictive value, Pos.LR: 
positive likelihood ratio; Neg.LR: negative likelihood ratio; *if chest pain onset >3h 
Supplemental 






ESC: European Society of Cardiology; Hs-cTnI: High-sensitivity cardiac troponin I; MACE: major adverse cardiac event; MACE+UA: 




















ESC hs-cTnI 0/1h-algorithm 0.9% 6.8% 0.2% 0.3% 0.2% 6.1% 0.0% 0.0% 0.1% 0.0% 0.1%

















Forest plots indicating sensitivity and negative predictive values (NPV) for subgroup 
analyses (A: age, B: gender, C: known CAD, D: CPO, E: eGFR) in both the troponin 
and the extended algorithm including interaction p-values. 
MACE: major adverse cardiac events; MACE+UA: major adverse cardiac event with 
unstable angina; CAD = coronary artery disease; CPO = chest pain onset; eGFR = 




Forest plots for sensitivity and negative predictive value 
including interaction p-value for the predefined subgroup 
analyses 
